| Literature DB >> 34843930 |
Zhaoyun Liu1, Yue Jia2, Yixuan Guo3, Hao Wang4, Rong Fu5.
Abstract
In recent years, methylation modification has been determined to be vital for the biological regulation of normal cells, tumor cells, and tumor microenvironment immune cells. Enhancer of zeste homology 2 (EZH2), a component of the Polycomb Repressive Complex 2 (PRC2), catalyzes the trimethylation of the downstream gene in the tri-methylates histone three lysine 27 (H3K27me3) position, which causes chromatin pyknosis, and thus, silences the expression of related genes. In this paper, we reviewed the role of EZH2 in regulating bone marrow mesenchymal stem cell differentiation and the immune cell function in tumor microenvironment, summarized all types of existing EZH2 inhibitors and the main clinical trials, and proposed relevant ideas for potential clinical applications.Entities:
Keywords: BMSC; EZH2; EZH2 inhibitor; Immunity; Multispectral differentiation
Mesh:
Substances:
Year: 2021 PMID: 34843930 DOI: 10.1016/j.critrevonc.2021.103547
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN: 1040-8428 Impact factor: 6.312